1. Key Insights
2. Executive Summary of Vernal keratoconjunctivitis (VKC)
3. Vernal keratoconjunctivitis (VKC): Market Overview at a Glance
3.1. Total Market Share (%) Distribution of VKC in 2017
3.2. Total Market Share (%) Distribution of VKC in 2030
4. Disease Background and Overview: Vernal keratoconjunctivitis (VKC)
4.1. Introduction
4.2. Signs and Symptoms of VKC
4.2.1. Signs
4.3. Causes
4.4. Risk Factors
4.5. Grades of VKC
4.6. Pathophysiology
4.6.1. Mediators in VKC
4.6.2. Cells in VKC
4.7. Histopathology
4.8. Diagnosis of VKC
5. Case Reports
5.1. Vernal Keratoconjunctivitis: A Teaching Case Report
5.2. Ocular surface disease: A case of vernal keratoconjunctivitis
5.3. Topical and Oral Cyclosporine for a Case of Severe Limbal Vernal Keratoconjunctivitis with Complete Corneal Involvement
5.4. Severe vernal keratoconjunctivitis successfully treated with subcutaneous omalizumab
5.5. Recalcitrant Atopic Keratoconjunctivitis in Children: A Case Report and Literature Review
6. Epidemiology and Patient Population
6.1. Key Findings
6.2. Epidemiology Methodology
7. United States Epidemiology
7.1. Assumptions and Rationale
7.2. Total Prevalent Population of Vernal Keratoconjunctivitis (VKC) in the United States
7.3. Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in the United States
7.4. Gender-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in the United States
7.5. Type-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) Based on Symptoms in the United States
7.6. Severity-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in the United States
7.7. Age-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in the United States
8. EU5 Epidemiology
8.1. Assumptions and Rationale
8.2. Germany Epidemiology
8.2.1. Total Prevalent Population of Vernal Keratoconjunctivitis (VKC) in Germany
8.2.2. Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in Germany
8.2.3. Gender-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in Germany
8.2.4. Type-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) Based on Symptoms in Germany
8.2.5. Severity-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in Germany
8.2.6. Age-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in Germany
8.3. France Epidemiology
8.3.1. Total Prevalent Population of Vernal Keratoconjunctivitis (VKC) in France
8.3.2. Diagnosed Prevalent Population of Vernal Keratoconjunctivitis (VKC) in France
8.3.3. Gender-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in France
8.3.4. Type-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in France
8.3.5. Severity-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in France
8.3.6. Age-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in France
8.4. Italy Epidemiology
8.4.1. Total Prevalent Population of Vernal Keratoconjunctivitis (VKC) in Italy
8.4.2. Diagnosed Prevalent Population of Vernal Keratoconjunctivitis (VKC) in Italy
8.4.3. Gender-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in Italy
8.4.4. Type-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in Italy
8.4.5. Severity-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in Italy
8.4.6. Age-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in Italy
8.5. Spain Epidemiology
8.5.1. Total Prevalent Population of Vernal Keratoconjunctivitis (VKC) in Spain
8.5.2. Diagnosed Prevalent Population of Vernal Keratoconjunctivitis (VKC) in Spain
8.5.3. Gender-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in Spain
8.5.4. Type-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in Spain
8.5.5. Severity-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in Spain
8.5.6. Age-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in Spain
8.6. United Kingdom Epidemiology
8.6.1. Total Prevalent Population of Vernal Keratoconjunctivitis (VKC) in the UK
8.6.2. Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in the UK
8.6.3. Gender-specific Prevalence of Vernal Keratoconjunctivitis (VKC) in the UK
8.6.4. Type-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in the United Kingdom
8.6.5. Severity-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in the United Kingdom
8.6.6. Age-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in the United Kingdom
9. Japan Epidemiology
9.1.1. Assumptions and Rationale
9.1.2. Total Prevalent Population of Vernal Keratoconjunctivitis (VKC) in Japan
9.1.3. Diagnosed Prevalent Population of Vernal Keratoconjunctivitis (VKC) in Japan
9.1.4. Gender-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in Japan
9.1.5. Type-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in Japan
9.1.6. Severity-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in Japan
9.1.7. Age-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in Japan
10. MEA Region Epidemiology
10.1. Assumptions and Rationale
10.2.Saudi Arabia Epidemiology
10.2.1. Total Prevalent Population of Vernal Keratoconjunctivitis (VKC) in Saudi Arabia
10.2.2. Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in Saudi Arabia
10.2.3. Gender-specific Prevalence of Vernal Keratoconjunctivitis (VKC) in Saudi Arabia
10.2.4. Type-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in Saudi Arabia
10.2.5. Severity-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in Saudi Arabia
10.2.6. Age-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in Saudi Arabia
10.3.Egypt Epidemiology
10.3.1. Total Prevalent Population of Vernal Keratoconjunctivitis (VKC) in Egypt
10.3.2. Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in Egypt
10.3.3. Gender-specific Prevalence of Vernal Keratoconjunctivitis (VKC) in Egypt
10.3.4. Type-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in Egypt
10.3.5. Severity-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in Egypt
10.3.6. Age-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in Egypt
11. China Epidemiology
11.1. Assumptions and Rationale
11.2. Total Prevalent Population of Vernal Keratoconjunctivitis (VKC) in China
11.3. Diagnosed Prevalent Population of Vernal Keratoconjunctivitis (VKC) in China
11.4. Gender-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in China
11.5. Type-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in China
11.6. Severity-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in China
11.7. Age-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in China
12. Russia Epidemiology
12.1. Assumptions and Rationale
12.2. Total Prevalent Population of Vernal Keratoconjunctivitis (VKC) in Russia
12.3. Diagnosed Prevalent Population of Vernal Keratoconjunctivitis (VKC) in Russia
12.4. Gender-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in Russia
12.5. Type-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in Russia
12.6. Severity-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in Russia
12.7. Age-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in Russia
13. Current Treatment and Medical Practices
13.1. Treatment of VKC
13.2. Practical management of VKC
13.3. Treatment Guidelines
13.3.1. Japanese guidelines for allergic conjunctival diseases 2017
14. Unmet Needs
15. Marketed Drugs
15.1. Verkazia/Verkacia: Santen
15.1.1. Product Description
15.1.2. Regulatory Milestones
15.1.3. Clinical Development
15.1.4. Safety and Efficacy
15.1.5. Product Profile
15.2. Lodoxamide/Alomide: Novartis Pharmaceuticals/Alcon
15.2.1. Product Description
15.2.2. Regulatory Milestones
15.2.3. Product Profile
15.3. Talymus/Tacrolimus: Senju Pharmaceutical
15.3.1. Product Description
15.3.2. Regulatory Milestones
15.3.3. Clinical Development
15.3.4. Safety and Efficacy
15.3.5. Product Profile
15.4. Papilock Mini: Santen
15.4.1. Product Description
15.4.2. Regulatory Milestones
15.4.3. Product Profile
16. Emerging Drugs
16.1. Antolimab (AK002): Allakos
16.1.1. Product Description
16.1.2. Regulatory Milestones
16.1.3. Clinical Development
16.1.4. Safety and Efficacy
16.1.5. Product Profile
16.2. Bertilimumab/iCo-008: iCo Therapeutics
16.2.1. Product Description
16.2.2. Regulatory Milestones
16.2.3. Safety and Efficacy
16.2.4. Product Profile
16.3. Nomacopan: Akari Therapeutics
16.3.1. Product Description
16.3.2. Regulatory Milestones
16.3.3. Clinical Development
16.3.4. Safety and Efficacy
16.3.5. Product Profile
17. Vernal Keratoconjunctivitis (VKC): 7MM Market Analysis
17.1. Key Findings
17.2. Market Methodology
17.3. Market Size of Vernal Keratoconjunctivitis (VKC) in the 6MM
17.4. Market Size of Vernal Keratoconjunctivitis (VKC) by Therapies in the 6MM
18. United States
18.1. 7MM: Market Outlook
18.2. United States Market Size
18.2.1. Total Market size of Vernal Keratoconjunctivitis (VKC) in the US
18.2.2. Market Size of Vernal Keratoconjunctivitis (VKC) by Therapies in the US
19. EU-5 countries
19.1.Germany Market Size
19.1.1. Total Market size of Vernal Keratoconjunctivitis (VKC) in Germany
19.1.2. Market Size of Vernal Keratoconjunctivitis (VKC) by therapies in Germany
19.2.France Market Size
19.2.1. Total Market size of Vernal Keratoconjunctivitis (VKC) in France
19.2.2. Market Size of Vernal Keratoconjunctivitis (VKC) by therapies in France
19.3.Italy Market Size
19.3.1. Total Market size of Vernal Keratoconjunctivitis (VKC) in Italy
19.3.2. Market Size of Vernal Keratoconjunctivitis (VKC) by therapies in Italy
19.4.Spain Market Size
19.4.1. Total Market size of Vernal Keratoconjunctivitis (VKC) in Spain
19.4.2. Market Size of Vernal Keratoconjunctivitis (VKC) by therapies in Spain
19.5.United Kingdom Market Size
19.5.1. Total Market size of Vernal Keratoconjunctivitis (VKC) in the United Kingdom
19.5.2. Market Size of Vernal Keratoconjunctivitis (VKC) by therapies in the UK
20. Japan
20.1. Japan Market Size
20.1.1. Total Market size of Vernal Keratoconjunctivitis (VKC) in Japan
20.1.2. Market Size of Vernal Keratoconjunctivitis (VKC) by therapies in Japan
21. MEA countries Market Outlook
21.1.Saudi Arabia Market Size
21.1.1. Total Market size of VKC in Saudi Arabia
21.1.2. Market Size of VKC by therapies in Saudi Arabia
21.2.Egypt Market Size
21.2.1. Total Market size of VKC in Egypt
21.2.2. Market Size of VKC by therapies in Egypt
22. China: Market Outlook
22.1. China Market Size
22.1.1. Total Market size of Vernal Keratoconjunctivitis (VKC) in China
22.1.2. Market Size of Vernal Keratoconjunctivitis (VKC) by therapies in China
23. Russia Market Outlook
23.1. Russia Market Size
23.1.1. Total Market size of Vernal Keratoconjunctivitis (VKC) in Russia
23.1.2. Market Size of Vernal Keratoconjunctivitis (VKC) by therapies in Russia
24. Market Drivers
25. Market Barriers
26. Reimbursement and Market Access
27. SWOT Analysis
28. KOL Views
29. Appendix
29.1. Bibliography
29.2. Report Methodology
30. DelveInsight Capabilities
31. Disclaimer
32. About DelveInsight
Table 1 :Summary of Vernal Keratoconjunctivitis (VKC), Market, Epidemiology and Key Events (2017–2030)Table 2 :Clinical grading (from 0 to 5) of vernal keratoconjunctivitis
Table 3 :Total Prevalent Population of Vernal Keratoconjunctivitis (VKC) in the Total Major Markets (2017–2030)
Table 4 :Total Prevalent Population of Vernal Keratoconjunctivitis (VKC) in the US (2017–2030)
Table 5 :Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in the US (2017–2030)
Table 6 :Gender-specific Diagnosed Prevalence of VKC in the US (2017–2030)
Table 7 :Type-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in the US (2017–2030)
Table 8 :Severity-specific Diagnosed Prevalence of VKC in the US (2017–2030)
Table 9 :Age-specific Diagnosed Prevalence of VKC in the US (2017–2030)
Table 10 :Total Prevalent Population of VKC in Germany (2017–2030)
Table 11 :Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in Germany (2017–2030)
Table 12 :Gender-Specific Diagnosed Prevalence of VKC in Germany (2017–2030)
Table 13 :Type-specific Diagnosed Prevalence of VKC in Germany (2017–2030)
Table 14 :Severity-specific Diagnosed Prevalence of VKC in Germany (2017–2030)
Table 15 :Age-specific Diagnosed Prevalence of VKC in Germany (2017–2030)
Table 16 :Total Prevalent Population of VKC in France (2017–2030)
Table 17 :Diagnosed Prevalent Population of VKC in France (2017–2030)
Table 18 :Gender-specific Diagnosed Prevalence of VKC in France (2017–2030)
Table 19 :Type-specific Diagnosed Prevalence of VKC in France (2017–2030)
Table 20 :Severity-specific Diagnosed Prevalence of VKC in France (2017–2030)
Table 21 :Age-specific Diagnosed Prevalence of VKC in France (2017–2030)
Table 22 :Total Prevalent Population of VKC in Italy (2017–2030)
Table 23 :Diagnosed Prevalent Population of VKC in Italy (2017–2030)
Table 24 :Gender-specific Diagnosed Prevalence of VKC in Italy (2017–2030)
Table 25 :Type-specific Diagnosed Prevalence of VKC in Italy (2017–2030)
Table 26 :Severity-specific Diagnosed Prevalence of VKC in Italy (2017–2030)
Table 27 :Age-specific Diagnosed Prevalence of VKC in Italy (2017–2030)
Table 28 :Total Prevalent Population of VKC in Spain (2017–2030)
Table 29 :Diagnosed Prevalent Population of VKC in Spain (2017–2030)
Table 30 :Gender-specific Diagnosed Prevalence of VKC in Spain (2017–2030)
Table 31 :Type-specific Diagnosed Prevalence of VKC in Spain (2017–2030)
Table 32 :Severity-specific Diagnosed Prevalence of VKC in Spain (2017–2030)
Table 33 :Age-specific Diagnosed Prevalence of VKC in Spain (2017–2030)
Table 34 :Total Prevalent Population of VKC in the UK (2017–2030)
Table 35 :Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in the UK (2017–2030)
Table 36 :Gender-Specific Prevalence of Vernal Keratoconjunctivitis (VKC) in the UK (2017–2030)
Table 37 :Type-specific Diagnosed Prevalence of VKC in the United Kingdom (2017–2030)
Table 38 :Severity-specific Diagnosed Prevalence of VKC in the United Kingdom (2017–2030)
Table 39 :Age-specific Diagnosed Prevalence of VKC in the UK (2017–2030)
Table 40 :Total Prevalent Population of VKC in Japan (2017–2030)
Table 41 :Diagnosed Prevalent Population of VKC in Japan (2017–2030)
Table 42 :Gender-specific Diagnosed Prevalence of VKC in Japan (2017–2030)
Table 43 :Type-specific Diagnosed Prevalence of VKC in Japan (2017–2030)
Table 44 :Severity-specific Diagnosed Prevalence of VKC in Japan (2017–2030)
Table 45 :Age-specific Diagnosed Prevalence of VKC in Japan (2017–2030)
Table 46 :Total Prevalent Population of VKC in Saudi Arabia (2017–2030)
Table 47 :Diagnosed Prevalence of VKC in Saudi Arabia (2017–2030)
Table 48 :Gender-Specific Prevalence of VKC in Saudi Arabia (2017–2030)
Table 49 :Type-specific Diagnosed Prevalence of VKC in Saudi Arabia (2017–2030)
Table 50 :Severity-specific Diagnosed Prevalence of VKC in Saudi Arabia (2017–2030)
Table 51 :Age-specific Diagnosed Prevalence of VKC in Saudi Arabia (2017–2030)
Table 52 :Total Prevalent Population of Vernal Keratoconjunctivitis (VKC) in Egypt (2017–2030)
Table 53 :Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in Egypt (2017–2030)
Table 54 :Gender-Specific Prevalence of Vernal Keratoconjunctivitis (VKC) in Egypt (2017–2030)
Table 55 :Type-specific Diagnosed Prevalence of VKC in Egypt (2017–2030)
Table 56 :Severity-specific Diagnosed Prevalence of VKC in Egypt (2017–2030)
Table 57 :Age-specific Diagnosed Prevalence of VKC in Egypt (2017–2030)
Table 58 :Total Prevalent Population of VKC in China (2017–2030)
Table 59 :Diagnosed Prevalent Population of VKC in China (2017–2030)
Table 60 :Gender-specific Diagnosed Prevalence of VKC in China (2017–2030)
Table 61 :Type-specific Diagnosed Prevalence of VKC in China (2017–2030)
Table 62 :Severity-specific Diagnosed Prevalence of VKC in China (2017–2030)
Table 63 :Age-specific Diagnosed Prevalence of VKC in China (2017–2030)
Table 64 :Total Prevalent Population of VKC in Russia (2017–2030)
Table 65 :Diagnosed Prevalent Population of VKC in Russia (2017–2030)
Table 66 :Gender-specific Diagnosed Prevalence of VKC in Russia (2017–2030)
Table 67 :Type-specific Diagnosed Prevalence of VKC in Russia (2017–2030)
Table 68 :Severity-specific Diagnosed Prevalence of VKC in Russia (2017–2030)
Table 69 :Age-specific Diagnosed Prevalence of VKC in Russia (2017–2030)
Table 70 :Topical ocular allergy medications for the treatment of vernal keratoconjunctivitis
Table 71 :Clinical grading of vernal keratoconjunctivitis and therapeutical approach
Table 72 :Verkazia, Clinical Trial Description, 2020
Table 73 :Tacrolimus, Clinical Trial Description, 2020
Table 74 :Antolimab (AK002), Clinical Trial Description, 2020
Table 75 :Nomacopan, Clinical Trial Description, 2020
Table 76 :Market Size of Vernal Keratoconjunctivitis (VKC) in the Total Markets in USD Million (2017–2030)
Table 77 :Market Size of Vernal Keratoconjunctivitis by therapies in the Total Markets, in USD Million (2017–2030)
Table 78 :The US Market Size of VKC in USD Million (2017–2030)
Table 79 :Market Size of Vernal Keratoconjunctivitis (VKC) by therapies in the US, in USD Million (2017–2030)
Table 80 :Germany Market Size of Vernal Keratoconjunctivitis (VKC) in USD Million (2017–2030)
Table 81 :Market Size of VKC by therapies in Germany, in USD Million (2017–2030)
Table 82 :France Market Size of Vernal Keratoconjunctivitis (VKC) in USD Million (2017–2030)
Table 83 :Market Size of VKC by therapies in France, in USD Million (2017–2030)
Table 84 :Italy Market Size of Vernal Keratoconjunctivitis (VKC) in USD Million (2017–2030)
Table 85 :Market Size of Vernal Keratoconjunctivitis (VKC) by therapies in Italy, in USD Million (2017–2030)
Table 86 :Spain Market Size of Vernal Keratoconjunctivitis (VKC) in USD Million (2017–2030)
Table 87 :Market Size of Vernal Keratoconjunctivitis (VKC) by therapies in Spain, in USD Million (2017–2030)
Table 88 :The UK Market Size of Vernal Keratoconjunctivitis (VKC) in USD Million (2017–2030)
Table 89 :Market Size of Vernal Keratoconjunctivitis (VKC) by therapies in the UK, in USD Million (2017–2030)
Table 90 :Japan Market Size of Vernal Keratoconjunctivitis (VKC) in USD Million (2017–2030)
Table 91 :Market Size of Vernal Keratoconjunctivitis (VKC) by therapies in Japan, in USD Million (2017–2030)
Table 92 :Topical medication for the treatment of Vernal Keratoconjunctivitis
Table 93 :Saudi Arabia Market Size of VKC in USD Million (2017–2030)
Table 94 :Market Size of VKC by therapies in Saudi Arabia, in USD Million (2017–2030)
Table 95 :Egypt Market Size of VKC in USD Million (2017–2030)
Table 96 :Market Size of VKC by therapies in Egypt, in USD Million (2017–2030)
Table 97 :China Market Size of Vernal Keratoconjunctivitis (VKC) in USD Million (2017–2030)
Table 98 :Market Size of VKC by therapies in China, in USD Million (2017–2030)
Table 99 :Russia Market Size of Vernal Keratoconjunctivitis (VKC) in USD Million (2017–2030)
Table 100 :Market Size of VKC by therapies in Russia, in USD Million (2017–2030)
List of Figures:
Figure 1 :Anatomy and symptoms of vernal keratoconjunctivitis
Figure 2 :Common symptoms of VKC
Figure 3 :Clinical sign of vernal keratoconjunctivitis
Figure 4 :Risk factors of VKC
Figure 5 :Different therapeutic approach proposed for the different vernal keratoconjunctivitis grades
Figure 6 :Total Prevalent Population of Vernal Keratoconjunctivitis (VKC) in the Total Major Markets (2017–2030)
Figure 7 :Total Prevalent Population of Vernal Keratoconjunctivitis (VKC) in the US (2017–2030)
Figure 8 :Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in the US (2017–2030)
Figure 9 :Gender-Specific Diagnosed Prevalence of VKC in the US (2017–2030)
Figure 10 :Type-specific Diagnosed Prevalence of VKC in the US (2017–2030)
Figure 11 :Severity-specific Diagnosed Prevalence of VKC in the US (2017–2030)
Figure 12 :Age-specific Diagnosed Prevalence of VKC in the US (2017–2030)
Figure 13 :Total Prevalent Population of Vernal Keratoconjunctivitis (VKC) in Germany (2017–2030)
Figure 14 :Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in Germany (2017–2030)
Figure 15 :Gender-Specific Diagnosed Prevalence of VKC in Germany (2017–2030)
Figure 16 :Type-specific Diagnosed Prevalence of VKC in Germany (2017–2030)
Figure 17 :Severity-specific Diagnosed Prevalence of VKC in Germany (2017–2030)
Figure 18 :Age-specific Diagnosed Prevalence of VKC in Germany (2017–2030)
Figure 19 :Total Prevalent Population of VKC in France (2017–2030)
Figure 20 :Diagnosed Prevalent Population of VKC in France (2017–2030)
Figure 21 :Gender-specific Diagnosed Prevalence of VKC in France (2017–2030)
Figure 22 :Type-specific Diagnosed Prevalence of VKC in France (2017–2030)
Figure 23 :Severity-specific Diagnosed Prevalence of VKC in France (2017–2030)
Figure 24 :Age-specific Diagnosed Prevalence of VKC in France (2017–2030)
Figure 25 :Total Prevalent Population of VKC in Italy (2017–2030)
Figure 26 :Diagnosed Prevalent Population of VKC in Italy (2017–2030)
Figure 27 :Gender-specific Diagnosed Prevalence of VKC in Italy (2017–2030)
Figure 28 :Type-specific Diagnosed Prevalence of VKC in Italy (2017–2030)
Figure 29 :Severity-specific Diagnosed Prevalence of VKC in Italy (2017–2030)
Figure 30 :Age-specific Diagnosed Prevalence of VKC in Italy (2017–2030)
Figure 31 :Total Prevalent Population of VKC in Spain (2017–2030)
Figure 32 :Diagnosed Prevalent Population of VKC in Spain (2017–2030)
Figure 33 :Gender-specific Diagnosed Prevalence of VKC in Spain (2017–2030)
Figure 34 :Type-specific Diagnosed Prevalence of VKC in Spain (2017–2030)
Figure 35 :Severity-specific Diagnosed Prevalence of VKC in Spain (2017–2030)
Figure 36 :Age-specific Diagnosed Prevalence of VKC in Spain (2017–2030)
Figure 37 :Total Prevalent Population of Vernal Keratoconjunctivitis (VKC) in the UK (2017–2030)
Figure 38 :Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in the UK (2017–2030)
Figure 39 :Gender-Specific Prevalence of Vernal Keratoconjunctivitis (VKC) in the UK (2017–2030)
Figure 40 :Type-specific Diagnosed Prevalence of VKC in the United Kingdom (2017–2030)
Figure 41 :Severity-specific Diagnosed Prevalence of VKC in the United Kingdom (2017–2030)
Figure 42 :Age-specific Diagnosed Prevalence of VKC in the UK (2017–2030)
Figure 43 :Total Prevalent Population of VKC in Japan (2017–2030)
Figure 44 :Diagnosed Prevalent Population of VKC in Japan (2017–2030)
Figure 45 :Gender-specific Diagnosed Prevalence of VKC in Japan (2017–2030)
Figure 46 :Type-specific Diagnosed Prevalence of VKC in Japan (2017–2030)
Figure 47 :Severity-specific Diagnosed Prevalence of VKC in Japan (2017–2030)
Figure 48 :Age-specific Diagnosed Prevalence of VKC in Japan (2017–2030)
Figure 49 :Total Prevalent Population of VKC in Saudi Arabia (2017–2030)
Figure 50 :Diagnosed Prevalence of VKC in Saudi Arabia (2017–2030)
Figure 51 :Gender-Specific Prevalence of VKC in Saudi Arabia (2017–2030)
Figure 52 :Type-specific Diagnosed Prevalence of VKC in Saudi Arabia (2017–2030)
Figure 53 :Severity-specific Diagnosed Prevalence of VKC in Saudi Arabia (2017–2030)
Figure 54 :Age-specific Diagnosed Prevalence of VKC in Saudi Arabia (2017–2030)
Figure 55 :Total Prevalent Population of Vernal Keratoconjunctivitis (VKC) in Egypt (2017–2030)
Figure 56 :Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in Egypt (2017–2030)
Figure 57 :Gender-Specific Prevalence of Vernal Keratoconjunctivitis (VKC) in Egypt (2017–2030)
Figure 58 :Type-specific Diagnosed Prevalence of VKC in Egypt (2017–2030)
Figure 59 :Severity-specific Diagnosed Prevalence of VKC in Egypt (2017–2030)
Figure 60 :Age-specific Diagnosed Prevalence of VKC in Egypt (2017–2030)
Figure 61 :Total Prevalent Population of VKC in China (2017–2030)
Figure 62 :Diagnosed Prevalent Population of VKC in China (2017–2030)
Figure 63 :Gender-specific Diagnosed Prevalence of VKC in China (2017–2030)
Figure 64 :Type-specific Diagnosed Prevalence of VKC in China (2017–2030)
Figure 65 :Severity-specific Diagnosed Prevalence of VKC in China (2017–2030)
Figure 66 :Age-specific Diagnosed Prevalence of VKC in China (2017–2030)
Figure 67 :Total Prevalent Population of VKC in Russia (2017–2030)
Figure 68 :Diagnosed Prevalent Population of VKC in Russia (2017–2030)
Figure 69 :Gender-specific Diagnosed Prevalence of VKC in Russia (2017–2030)
Figure 70 :Type-specific Diagnosed Prevalence of VKC in Russia (2017–2030)
Figure 71 :Severity-specific Diagnosed Prevalence of VKC in Russia (2017–2030)
Figure 72 :Age-specific Diagnosed Prevalence of VKC in Russia (2017–2030)
Figure 73 :Allergist and Eye Care Specialists: Multidisciplinary Approach
Figure 74 :Treatment algorithm for vernal keratoconjunctivitis
Figure 75 :Treatment of ACDs: proliferative (vernal keratoconjunctivitis)
Figure 76 :Unmet Needs
Figure 77 :Market Size of Vernal Keratoconjunctivitis (VKC) in the Total Markets in USD Million (2017–2030)
Figure 78 :Market Size of VKC by therapies in the Total Markets, in USD Million (2017–2030)
Figure 79 :Market Size of Vernal Keratoconjunctivitis (VKC) in the US, USD Millions (2017–2030)
Figure 80 :Market Size of Vernal Keratoconjunctivitis (VKC) by therapies in the US, in USD Million (2017–2030)
Figure 81 :Market Size of Vernal Keratoconjunctivitis (VKC) in Germany, USD Millions (2017–2030)
Figure 82 :Market Size of VKC by therapies in Germany, in USD Million (2017–2030)
Figure 83 :Market Size of Vernal Keratoconjunctivitis (VKC) in France, USD Millions (2017–2030)
Figure 84 :Market Size of VKC by therapies in France, in USD Million (2017–2030)
Figure 85 :Market Size of Vernal Keratoconjunctivitis (VKC) in Italy, USD Millions (2017–2030)
Figure 86 :Market Size of Vernal Keratoconjunctivitis (VKC) by therapies in Italy in USD Million (2017–2030)
Figure 87 :Market Size of Vernal Keratoconjunctivitis (VKC) in Spain, USD Millions (2017–2030)
Figure 88 :Market Size of Vernal Keratoconjunctivitis (VKC) by therapies in Spain in USD Million (2017–2030)
Figure 89 :Market Size of Vernal Keratoconjunctivitis (VKC) in the UK, USD Millions (2017–2030)
Figure 90 :Market Size of Vernal Keratoconjunctivitis (VKC) by therapies in the UK in USD Million (2017–2030)
Figure 91 :Market Size of Vernal Keratoconjunctivitis (VKC) in Japan, USD Millions (2017–2030)
Figure 92 :Market Size of VKC by therapies in Japan in USD Million (2017–2030)
Figure 93 :Market Size of VKC in Saudi Arabia, USD Millions (2017–2030)
Figure 94 :Market Size of VKC by therapies in Saudi Arabia, in USD Million (2017–2030)
Figure 95 :Market Size of VKC in Egypt, USD Millions (2017–2030)
Figure 96 :Market Size of VKC by therapies in Egypt, in USD Million (2017–2030)
Figure 97 :Market Size of Vernal Keratoconjunctivitis (VKC) in China, USD Millions (2017–2030)
Figure 98 :Market Size of VKC by therapies in China in USD Million (2017–2030)
Figure 99 :Market Size of Vernal Keratoconjunctivitis (VKC) in Russia, USD Millions (2017–2030)
Figure 100 :Market Size of VKC by therapies in Russia in USD Million (2017–2030)
Figure 101 :Market Drivers
Figure 102 :Market Barriers
Figure 103 :SWOT analysis of vernal keratoconjunctivitis
Figure 104 :KOL Views
Figure 105 :KOL Views Continued..
【免責事項】
https://www.marketreport.jp/reports-disclaimer